Canaccord analyst Edward Nash lowered the firm’s price target on Ventyx Biosciences to $15 from $16 and keeps a Buy rating on the shares. The firm hosted a virtual investor conference and reported clinical results from the company’s NLRP3 program as well as its pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTYX:
- Wells Fargo more bullish on Ventyx Biosciences, upgrades to Overweight
- Ventyx Biosciences upgraded to Overweight from Equal Weight at Wells Fargo
- Ventyx Biosciences upgraded to Outperform on new focus at Oppenheimer
- Ventyx Biosciences upgraded to Outperform from Perform at Oppenheimer
- Ventyx Biosciences to hold virtual investor event
